Constipation on Semaglutide: A Practical Guide

Published May 25, 2026Updated May 27, 2026Last reviewed May 25, 2026

For the broader cluster context, see the semaglutide side effects and safety hub.

Author: HealthRX Editorial Team Medically reviewed by: Dr. Mark Halpern, MD (Internal Medicine, Obesity Medicine) Last clinical review: May 2026

Compounded semaglutide is not FDA-approved. This article is patient education and does not replace consultation with a licensed clinician.

Last March, Dana in Phoenix messaged her prescriber at 11 p.m. on a Tuesday. She was six weeks into compounded semaglutide, had just bumped from 0.5 mg to 1.0 mg, and hadn't had a bowel movement in five days. "I feel like I swallowed a brick," she wrote. "Is this normal or am I broken?" Her clinician responded the next morning with a short protocol: more water, psyllium husk, a 20-minute walk after dinner, and polyethylene glycol if nothing moved within 48 hours. By Friday, Dana was back on track. Her experience is so common it could be a template.

This is the article for the Danas. No fluff, no reassuring platitudes about "listening to your body." Just the clinical picture, the trial data, and a step-by-step plan for what is arguably the most annoying side effect of GLP-1 therapy.

This guide sits inside the broader Compounded Semaglutide Side Effects and Safety cluster, which is part of the compounded semaglutide pillar guide.

The Trial Data on GI Side Effects (Including Constipation)

The published trial record for semaglutide is unusually thorough for an obesity drug. Across STEP-1, STEP-3, STEP-4, SUSTAIN-6, LEADER, and SELECT, gastrointestinal events were the single most common class of adverse effects. Nausea gets all the press, but constipation quietly sits in the top five across nearly every trial arm.

In STEP-1, roughly 20 percent of patients reported nausea at some point during the study. Constipation rates were lower but still clinically meaningful, consistently appearing in the GI adverse event tables alongside decreased appetite, diarrhea, and mild bloating. Severe GI events were uncommon. The pattern across trials is clear: these symptoms cluster around dose escalation, peak in the first one to two weeks after an increase, and usually settle on their own.

A quick note on safety context. The Wegovy and Ozempic labels include a boxed warning about thyroid C-cell tumors based on rodent studies. That risk has not shown up at population scale in human outcome trials like SELECT or LEADER. Pancreatitis was reported in a small fraction of patients across trials, with rates that did not differ significantly between semaglutide and placebo arms. Most prescribers screen for personal or family history of medullary thyroid carcinoma or MEN2 before writing the script. These are real considerations, but they are distinct from the GI tolerability issues this article focuses on.

Why Semaglutide Slows Your Gut Down

Here's the thing about GLP-1 receptor agonists: they work, in part, by slowing gastric emptying. That's a feature, not a bug. Slower stomach emptying means you feel full longer, eat less at each meal, and experience more sustained satiety between meals. The weight loss depends on it.

The catch is that slowing the top of the digestive tract has downstream consequences. Think of it like a highway on-ramp metering light. If you reduce the flow entering the highway, traffic further down thins out too. The colon gets less material, less frequently, and the stool that does arrive has had more water extracted from it because transit time is longer. Add in the reduced food volume that most patients experience (people on semaglutide simply eat less), and you have a recipe for hard, infrequent stools.

This is not a sign that something is wrong with you. It's a predictable pharmacologic consequence of how the drug works. That doesn't make it less miserable, but it does mean there's a logical set of interventions.

The Playbook: Four Steps, In Order

Constipation on semaglutide is one of the most common reasons patients reach out between visits. Clinicians who treat large GLP-1 panels tend to run the same protocol, and it works in a specific sequence. Skipping to step four rarely helps if you haven't addressed steps one through three.

Step 1: Water. This sounds almost insultingly simple, but most patients on semaglutide are mildly dehydrated and don't realize it. When you eat less, you also take in less water from food (fruits, soups, vegetables all contribute meaningful fluid). The first and cheapest intervention is pushing daily fluid intake up. Sixty-four ounces is a minimum; many clinicians aim higher depending on body weight and climate.

Step 2: Fiber. Both soluble and insoluble fiber matter. The target is 25 to 35 grams per day from food. If you're eating 1,200 calories a day because your appetite has cratered (common in the first months of therapy), hitting that target from diet alone is genuinely difficult. A psyllium-based fiber supplement bridges the gap. Start low and increase gradually, because dumping a tablespoon of Metamucil into an already sluggish gut can make bloating worse before it makes constipation better.

Step 3: Movement. Daily walking, even 20 minutes at a pace that wouldn't impress anyone, supports gut motility independent of any medication change. There's nothing magical here. Physical activity stimulates the smooth muscle contractions that push contents through the colon. A post-dinner walk is the single most underused constipation intervention in medicine.

Step 4: Osmotic laxative. Polyethylene glycol (MiraLAX is the common brand) draws water into the colon and softens stool. It's appropriate when steps one through three aren't enough, used short-term and under clinician guidance. It's not habit-forming in the way stimulant laxatives can be, and it's well tolerated.

Stimulant laxatives (senna, bisacodyl) have a role but are not first-line for chronic GLP-1-related constipation. If symptoms persist beyond one to two weeks of consistent intervention across all four steps, the prescriber should be consulted to rule out other contributors.

When to Actually Call Your Prescriber

The threshold for picking up the phone should be lower than most patients assume. Five days without a bowel movement despite the full playbook? Call. Severe abdominal pain, especially in the upper abdomen or radiating to the back? Call. Persistent vomiting for more than a day, signs of dehydration (dark urine, dizziness on standing), jaundice, severe headache, or vision changes? Call promptly.

Most GI side effects don't rise to this level. They're uncomfortable, not dangerous. But the distinction matters, and patients tend to err on the side of toughing it out longer than they should.

Dose Timing and the Constipation Connection

The pattern is almost always tied to dose escalation. You bump from 0.25 to 0.5 mg, things get sluggish for a week, then normalize. You bump from 0.5 to 1.0 mg, same cycle repeats. Some patients experience constipation that's genuinely persistent at a given dose, and for those patients, the clinical conversation becomes: is this dose producing enough benefit to justify the tolerability trade-off, or should we hold here?

My honest opinion (and this is an editorial judgment, not clinical advice): too many patients and programs are in a rush to hit the maximum dose. The STEP trials used aggressive titration schedules because they were designed to measure the drug's maximum effect. In clinical practice, there is no prize for getting to 2.4 mg fastest. Holding at a dose where constipation is manageable and weight loss is still proceeding is often the smarter play.

The Compounded Semaglutide Context

Compounded semaglutide is prepared by a licensed compounding pharmacy under a clinician's prescription. It uses the same active molecule as Wegovy and Ozempic. The clinical evidence for how semaglutide behaves in the body, including its GI side effect profile, comes from trials of the branded products. The compounded preparation has not been independently tested in randomized trials at the same scale.

That distinction matters for regulatory purposes. It does not mean the constipation you experience on compounded semaglutide is somehow different from what trial participants experienced. Same molecule, same mechanism, same downstream effects on gut motility.

The regulatory status, oversight, and supply chain for compounded preparations are distinct from branded products. Compounded semaglutide is not FDA-approved. The clinician relationship, the quality of the compounding pharmacy (503A or 503B), and the responsiveness of your program when side effects arise matter more than many patients realize. A program that responds to "I haven't had a bowel movement in five days" with a same-day protocol adjustment is doing its job. One that takes a week to respond is not.

Four Misconceptions Worth Correcting

"If I'm getting side effects, the drug must be working better." Trial data don't support this. In STEP-1 and STEP-3, patients with minimal GI symptoms and patients with pronounced GI symptoms both achieved meaningful weight loss. Side effect intensity is not a proxy for efficacy.

"Compounded semaglutide is basically the same as Wegovy, FDA-wise." It isn't. Compounding pharmacies operate under a different regulatory framework with different oversight. Same active ingredient, different legal and quality assurance category.

"The medication does the work; lifestyle is optional." STEP-3, which paired semaglutide with a structured lifestyle intervention, produced greater mean weight loss than STEP-1, which used the medication with standard counseling. Lifestyle is additive. On the constipation front specifically, the fiber-water-movement triad is not a suggestion. It's the difference between tolerating the drug and quitting it.

"Once I stop, everything goes back to normal." STEP-4 documented partial weight regain over the 48 weeks after participants switched from active drug to placebo at week 20. The chronic biology of weight regulation reasserts itself without pharmacologic support, just as blood pressure trends back up when you stop antihypertensives. This doesn't mean you're trapped, but it does mean the plan for what happens after stopping should exist before you start.

Adjacent Reading

Where This Fits

This article is part of the Compounded Semaglutide Side Effects and Safety cluster. For a broader treatment of the molecule, the regulatory pathway, the 503A and 503B compounding framework, and the clinical evidence base, the compounded semaglutide pillar guide is the primary reference on this site.

Frequently Asked Questions

Are the side effects of compounded semaglutide different from Wegovy or Ozempic?

The active ingredient is the same. The side effect profile reported in compounded semaglutide programs mirrors what was reported in SUSTAIN, STEP-1, and STEP-3 for the branded products. Compounded preparations are not FDA-approved and have not been independently studied at the same scale.

When should a side effect trigger a call to the prescriber?

Severe abdominal pain, persistent vomiting, signs of dehydration, jaundice, or vision changes are reasons to contact the prescribing clinician promptly. Most GI side effects are dose-related and improve with adjustment.

Do side effects predict effectiveness?

No. There is no reliable evidence that nausea, constipation, or other GI side effects predict greater weight loss. Trial data show meaningful weight loss in patients with minimal side effects as well as those with more pronounced symptoms.

How long does constipation on semaglutide typically last?

Most patients experience constipation in the one to two weeks following a dose increase. With consistent hydration, fiber, and movement, it usually resolves. Persistent constipation beyond two weeks of active management warrants a conversation with the prescriber.

Is it safe to use a laxative while on semaglutide?

Osmotic laxatives like polyethylene glycol are routinely used short-term under clinician guidance. Stimulant laxatives are appropriate in some situations but are not first-line for ongoing GLP-1-related constipation. Always check with your prescriber before adding anything to the regimen.

Compliance and Authorship

This article references the STEP-1, STEP-3, STEP-4, SUSTAIN, SELECT, and LEADER clinical trial programs where appropriate. It is intended as patient education and does not replace consultation with a licensed clinician.